Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV)

This study evaluates the overall survival and disease free survival of melanoma patients that were treated with an autologous melanoma cell vaccine, administered as a post-operative adjuvant. Included are 43 patients with totally resected metastatic melanoma (28-AJCC stage III, 15-AJCC stage IV), wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lotem, M, Peretz, T, Drize, O, Gimmon, Z, EL, D Ad, Weitzen, R, Goldberg, H, David, I Ben, Prus, D, Hamburger, T, Shiloni, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746603/
https://www.ncbi.nlm.nih.gov/pubmed/12085200
http://dx.doi.org/10.1038/sj.bjc.6600251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746603/
https://www.ncbi.nlm.nih.gov/pubmed/12085200
http://dx.doi.org/10.1038/sj.bjc.6600251

Ejemplares similares